The biggest obstacles to growth in life sciences
Growth in life sciences is often discussed in terms of innovation, funding, and market expansion.
In the State of Life Sciences Marketing Report 2026, professionals from biotech, medtech, and pharma were asked how they define growth and what limits their ability to achieve it.
The findings present a structured picture of ambition alongside constraint.
Table of contents
How growth is defined
Before examining obstacles, it is important to understand what growth means within the sector.
According to the report:
- 63% of respondents define growth primarily as revenue increase
- 48% associate growth with access to new markets
- 37% mention portfolio expansion
- 31% link growth to lead generation
- 42% highlight customer retention
Growth is therefore predominantly framed in commercial and strategic terms. Revenue expansion and market access outweigh lead generation as primary definitions.
This framing provides context for how obstacles are experienced.
The primary obstacles to growth
When asked about the biggest obstacles to growth, respondents identified the following:
- 58% cite R&D / product development delays
- 52% cite limited budget or resources
- 40% cite strong competition
- 31% cite limited access to talent or expertise
- 31% cite regulatory & compliance requirements
- 23% cite technological limitations
- 21% cite low brand awareness
These figures indicate that growth limitations are embedded across development timelines, funding realities, market dynamics, and compliance requirements.
Operational constraints
With 58% of respondents citing R&D delays as the largest obstacle, development timelines represent the most significant reported barrier to growth.
In research-intensive industries, long validation cycles and product development processes directly influence when commercial expansion becomes possible. Growth objectives therefore exist within extended innovation timelines.
This finding aligns with the commercial definition of growth: revenue expansion is the primary goal, yet the underlying product lifecycle may slow that expansion.
Resource and capacity constraints
More than half of respondents (52%) identify limited budgets and resources as a growth barrier.
Additionally, 31% report lack of talent as an obstacle.
These figures suggest that organisations operate within defined capacity limits. Financial and human resources influence the speed at which commercial initiatives can be executed, particularly in global or highly regulated environments.
Competitive and market pressures
40% of respondents cite strong competition as a constraint.
In parallel, 21% mention brand awareness.
These data points show that market visibility and differentiation remain relevant considerations, though they are not the most dominant obstacles compared to operational or financial limitations.
Regulatory and technological constraints
Regulatory complexity is cited by 31% of respondents.
Technological limitations are cited by 23%.
In life sciences, regulatory oversight and technical requirements shape how quickly organisations can scale products or expand into new markets. These structural factors influence commercial pacing.
Conclusion
The State of Life Sciences Marketing Report 2026 shows that growth in life sciences is primarily defined in commercial terms, especially revenue expansion.
The main obstacles are operational (R&D delays), financial (budget constraints), competitive (market pressure), and regulatory.
Together, these findings illustrate how growth ambitions and structural constraints coexist within the sector.
Questions or need guidance? Send us a message, we’re happy to help!
